Vyriad closed a $25 million final tranche of its series B, bringing total Series B proceeds to $85 million. The company said the financing will support first‑in‑human testing of VV‑169, an in‑vivo CAR‑T candidate intended for relapsed or refractory multiple myeloma. Vyriad plans to move VV‑169 into clinical testing and expand capacity for oncolytic and cell‑based programs. The raise signals investor interest in in‑vivo cell‑engineering approaches and their potential to lower logistical barriers to adopt CAR‑based therapies.